Curaleaf Holdings (CURLF) Cash from Financing Activities (2019 - 2024)
Curaleaf Holdings (CURLF) recorded quarterly Cash from Financing Activities of -$6.6 million in Q4 2024, up 46.11% quarter-over-quarter from -$12.2 million in Q3 2024, and up 61.27% on a YoY basis from -$4.1 million in Q1 2024.
Curaleaf Holdings (CURLF) Cash from Financing Activities (2019 - 2024) Analysis & Trends
Curaleaf Holdings' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at -$6.6 million for Q4 2024.
- In Q4 2024, Cash from Financing Activities rose 61.27% year-over-year to -$6.6 million; the TTM figure through Dec 2024 stood at -$54.1 million (up 19.26% YoY), while the FY2025 annual figure was -$73.5 million, down 35.86% from the prior year.
- Cash from Financing Activities was -$6.6 million for Q4 2024 at Curaleaf Holdings, up from -$12.2 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $28.6 billion in Q2 2023 to a low of -$28.6 billion in Q1 2023.
- Historically, Cash from Financing Activities has averaged $27.4 million across 5 years, with a median of $1.7 million in 2020.
- Biggest YoY gain for Cash from Financing Activities was 59634.52% in 2023; the steepest drop was 171254.23% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at $3.4 million in 2020, then jumped by 2674.62% to $95.2 million in 2021, then sank by 59.52% to $38.6 million in 2022, then tumbled by 144.07% to -$17.0 million in 2023, then soared by 61.27% to -$6.6 million in 2024.
- The last three Cash from Financing Activities figures came in at -$6.6 million (Q4 2024), -$12.2 million (Q3 2024), and -$15.7 billion (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | -11.62 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -77.88 Mn |
| 10 | Curaleaf Holdings | - | - | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -6.58 Mn |
| Dec 31, 2024 | -6.58 Mn |
| Sep 30, 2024 | -12.21 Mn |
| Sep 30, 2024 | -12.21 Mn |
| Jun 30, 2024 | -15.73 Bn |
| Jun 30, 2024 | -15.73 Bn |
| Mar 31, 2024 | 15.70 Bn |
| Mar 31, 2024 | 15.70 Bn |
| Dec 31, 2023 | -16.99 Mn |
| Dec 31, 2023 | -16.99 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Jun 30, 2023 | 28.59 Bn |
| Jun 30, 2023 | 28.59 Bn |
| Mar 31, 2023 | -28.65 Bn |
| Mar 31, 2023 | -28.65 Bn |
| Dec 31, 2022 | 38.55 Mn |
| Dec 31, 2022 | 38.55 Mn |
| Sep 30, 2022 | -27.89 Mn |
| Sep 30, 2022 | -27.89 Mn |